Clinical Trial Search

Primary: Participants Self-rating of Pain Using the Wong-Baker FACES Pain Rating Scale. — 42; 38; 6; 8 Participants

Primary: Changes in Smoking-related Gene Expression Signature Score in Nasal Epithelium — -1.11; 1.39 gene expression signature score — p=0.04

Primary: PTSD Symptoms — 38.7; 52.8; 32.0; 51.5 units on a scale

Primary: Number of Side-effects — 4; 2 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Perampanel — 21; 11…

Primary: Proportion of Patients P0 at Surgery — 0 Participants

Primary: Phase 1b and Phase 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 3; 3; 90; 82…

Primary: Change From Baseline in Fraction of Exhaled Nitric Oxide (FeNO) Over Time Following the Cessation of Repeat Dose Treatment With FF/VI — 1.042; 0.371; 0.985; 0.321 Ratio…

Primary: PET Detection of Primary Prostate Cancer — 6; 7 Participants

Primary: Overall Response Rate (ORR) of IMGN901 in Participants CD56 Expressing Hematological Malignancies — 0; 0; 0 Participants

Primary: Baseline Pre-dose Forced Expiratory Volume in One Second (FEV1) — 2.264; 2.234 Liter

Primary: Number of Patients Showing a Reduction by at Least 50% of Peripheral Blood BCR-ABL/ABL Ratio Compared to the Individual Prevaccine Level — 22; 14 participants

Primary: Percentage of Participants With a Confirmed Objective Tumor Response Using RECIST Version 1.0 — 22; 14.3 percentage of participants

Primary: Change in Hemoglobin From Baseline to the End of 8-week Treatment Period — 10.8; 11.1 g/dL

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -0.44; -1.23; -1.31; -1.40 Percentage of glycosylated hemoglobin — p=<.001